To the Editor We dispute the conclusion that fluorodeoxyglucose (FDG) PET-CT is of questionable value to patients with hepatic metastases from colorectal cancer being evaluated for curative intent surgery.1 When current best surgical practice infrequently leads to cure and has associated morbidity and cost, is a 9% improvement in surgical management of questionable value to patients?
Hofman MS, Ware RE, Thomson BN. PET Screening for Metastatic Colorectal Adenocarcinoma. JAMA. 2014;312(12):1255-1256. doi:10.1001/jama.2014.9850